Use of Autologous Serum Tears for the Treatment of Ocular Surface Disease From Patients With Systemic Autoimmune Diseases

• Published in: American journal of ophthalmology Vol. 189; pp. 65 - 70
• Main Authors: Ali, Tayyeba K., Gibbons, Allister, Cartes, Cristián, Zarei-Ghanavati, Siamak, Gomaa, Mohamed, Gonzalez, Ingrid, Gonzalez, Astrid E., Ozturk, Hilal E., Betancurt, Carolina, Perez, Victor L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2018; Elsevier Limited
• Subjects: Adult; Aged; Aged, 80 and over; Autoimmune diseases; Autoimmune Diseases - physiopathology; Autoimmune Diseases - therapy; Biological Therapy - methods; Cornea; Corneal Diseases - physiopathology; Corneal Diseases - therapy; Dry Eye Syndromes - physiopathology; Dry Eye Syndromes - therapy; Female; Follow-Up Studies; Glucocorticoids - therapeutic use; Humans; Immunosuppressive Agents - therapeutic use; Male; Middle Aged; Ophthalmic Solutions; Ophthalmology; Patients; Retrospective Studies; Serum - physiology; Visual Acuity - physiology; United States > US

To describe the safety and efficacy of autologous serum tears (AST) in managing ocular surface disease resistant to conventional therapy in patients with systemic autoimmune disease(s). Retrospective, interventional case series. Records of patients from 2009 to 2015 with systemic autoimmune disease...